Curcumin may be promising treatment for cancer
the ONA take:
Curcumin, a compound found in turmeric, may be a promising treatment for a variety of cancers and other inflammatory diseases, according to an international review published in Molecules.
Gautam Sethi, PhD, of Curtin University in Australia looked at past clinical trials that used curcumin in patients with cancer and concluded that it was a safe and effective method of treating cancer.
“To treat cancer you need multi-targeted agents, better than mono-targeted agents, which have been used for the past few years,” Dr. Sethi said. “They are more effective in treating cancer as it has been found that several genes are mutated in a given cancer.”
Oncogenic genes, he claimed, can be deregulated in cancer using curcumin. Therefore, it is effective for patients with multiple myeloma and those with fatal pancreatic cancer, for which there are no drug treatments.
Curcumin counteracts the effects of cyclophosphamide, however, and is therefore not as effective in patients undergoing breast cancer treatment.
Dr. Sethi recommends that people use turmeric more often in everyday cooking.
Curcumin, a compound found in turmeric, may be a promising treatment for a variety of cancers.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|